BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 17101065)

  • 1. Combining imatinib with surgery in gastrointestinal stromal tumors: rationale and ongoing trials.
    Eisenberg BL
    Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S24-9. PubMed ID: 17101065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budgetary impact of treatment with adjuvant imatinib for 1 year following surgical resection of Kit-positive localized gastrointestinal stromal tumors.
    Rubin JL; Taylor DC; Sanon M; Coombs JH; Bollu VK
    J Manag Care Pharm; 2010 Sep; 16(7):482-91. PubMed ID: 20726677
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined surgical and molecular therapy: the gastrointestinal stromal tumor model.
    Gold JS; Dematteo RP
    Ann Surg; 2006 Aug; 244(2):176-84. PubMed ID: 16858179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of surgery and imatinib mesylate in the treatment of advanced gastrointestinal stromal tumor: a systematic review.
    Cirocchi R; Farinella E; La Mura F; Cavaliere D; Avenia N; Verdecchia GM; Giustozzi G; Noya G; Sciannameo F
    Tumori; 2010; 96(3):392-9. PubMed ID: 20845798
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
    Blesius A; Cassier PA; Bertucci F; Fayette J; Ray-Coquard I; Bui B; Adenis A; Rios M; Cupissol D; Pérol D; Blay JY; Le Cesne A
    BMC Cancer; 2011 Feb; 11():72. PubMed ID: 21324142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
    Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M
    Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical update and emerging trends in imatinib treatment for gastrointestinal stromal tumor.
    De Giorgi U; Pupi A; Turrisi G; Montenora I; Morini S; Fayyaz M; De Simone M; Fiorentini G
    Rev Recent Clin Trials; 2007 Jan; 2(1):43-8. PubMed ID: 18473987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal stromal tumors: imatinib and beyond.
    Schnadig ID; Blanke CD
    Curr Treat Options Oncol; 2006 Nov; 7(6):427-37. PubMed ID: 17032555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological complete response in advanced gastrointestinal stromal tumor after imatinib therapy.
    Melichar B; Voboril Z; Nozicka J; Ryska A; Urminská H; Vanecek T; Michal M
    Intern Med; 2005 Nov; 44(11):1163-8. PubMed ID: 16357454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Successful resection of locally advanced gastrointestinal stromal tumor of the ampulla of Vater after treatment with imatinib].
    Park JE; Dong SH; Cho KH; Jang JY; Kim HJ; Kim BH; Chang YW; Chang R
    Korean J Gastroenterol; 2010 Jul; 56(1):39-44. PubMed ID: 20695129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Therapy of Gastrointestinal Stromal Tumors.
    Rutkowski P; Hompes D
    Surg Oncol Clin N Am; 2016 Oct; 25(4):735-59. PubMed ID: 27591496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiologic assessment of earliest, best, and plateau response of gastrointestinal stromal tumors to neoadjuvant imatinib prior to successful surgical resection.
    Tirumani SH; Shinagare AB; Jagannathan JP; Krajewski KM; Ramaiya NH; Raut CP
    Eur J Surg Oncol; 2014 Apr; 40(4):420-8. PubMed ID: 24238762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in therapy for gastrointestinal stromal tumors.
    Maki RG
    Curr Oncol Rep; 2007 May; 9(3):165-9. PubMed ID: 17430686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of imatinib resistance associated with downregulation of c-kit expression in recurrent gastrointestinal stromal tumor (GIST): optimal timing of resection.
    Dudeja V; Armstrong LH; Gupta P; Ansel H; Askari S; Al-Refaie WB
    J Gastrointest Surg; 2010 Mar; 14(3):557-61. PubMed ID: 20033343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is imatinib justified as an adjuvant chemotherapy for patients with recurrent gastrointestinal stromal tumors.
    Lai IR; Hu RH; Chang KJ
    Hepatogastroenterology; 2005; 52(63):826-8. PubMed ID: 15966213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease progression following imatinib failure in gastrointestinal stromal tumors: role of surgical therapy.
    Jamali FR; Darwiche SS; El-Kinge N; Tawil A; Soweid AM
    Oncologist; 2007 Apr; 12(4):438-42. PubMed ID: 17470686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
    Croom KF; Perry CM
    Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal stromal tumors: diagnosis and treatment.
    Acín-Gándara D; Pereira-Pérez F; Castaño-Pascual A; Durán-Poveda M; Antequera-Pérez A; Miliani-Molina C
    Cir Cir; 2012; 80(1):44-51. PubMed ID: 22472152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumors: current management.
    Pisters PW; Patel SR
    J Surg Oncol; 2010 Oct; 102(5):530-8. PubMed ID: 20063363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.